Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Buy" from Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been given a consensus rating of "Buy" by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $9.17.

A number of analysts have commented on the company. Morgan Stanley began coverage on Sana Biotechnology in a report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Sana Biotechnology in a research report on Tuesday, June 24th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SANA. Cerity Partners LLC purchased a new stake in Sana Biotechnology during the 4th quarter valued at approximately $25,000. Tower Research Capital LLC TRC lifted its stake in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after purchasing an additional 10,548 shares in the last quarter. Syon Capital LLC purchased a new stake in Sana Biotechnology in the 4th quarter worth $27,000. Ameriprise Financial Inc. bought a new position in shares of Sana Biotechnology during the 4th quarter valued at about $29,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Sana Biotechnology in the first quarter worth about $29,000. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock traded up $0.18 during midday trading on Thursday, hitting $4.63. The company had a trading volume of 5,014,391 shares, compared to its average volume of 3,912,467. The company has a 50 day moving average of $2.72 and a 200 day moving average of $2.53. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $7.30. The stock has a market capitalization of $1.04 billion, a P/E ratio of -5.26 and a beta of 1.86.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. Equities research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.